Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study (First in Humans) of the Amblyomin-X in the Treatment of Patients With Advanced Solid Tumors Refractory or Without Indication / Access to Standard Treatment

NCT03120130 is registered in ClinicalTrials.gov with União Química Farmacêutica Nacional S/A as lead sponsor.

NCT NCT03120130
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03120130 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study (First in Humans) of the Amblyomin-X in the Treatment of Patients With Advanced Solid Tumors Refractory or Without Indication / Access to Standard Treatment
Lead sponsor
União Química Farmacêutica Nacional S/A
Phase
Phase 1
Overall status
Suspended
Start date
February 15, 2021
Completion date
May 22, 2022
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer